Combination of vaccination and OX40 agonists
The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
1. A combination kit comprising:
(i) a composition comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and
(ii) a composition comprising an OX40 agonist, wherein the OX40 agonist comprises an OX40-binding antibody, or an antigen-binding fragment thereof, or a nucleic-acid encoded an OX40-binding antibody or an antigen-binding fragment thereof.
2. The combination kit of claim 1 , wherein the OX40 agonist comprises an OX40-binding antibody.
3. The combination kit of claim 2 , wherein the OX40 agonist comprises a nucleic-acid encoded an OX40-binding antibody or an antigen-binding fragment thereof.
4. The combination kit of claim 3 , wherein the nucleic-acid encoded an OX40-binding antibody or an antigen-binding fragment thereof is a mRNA.
5. The combination kit of claim 1 , wherein the OX40-binding antibody is monoclonal antibody 9B12.
6. The combination kit of claim 1 , wherein the at least one RNA is an isolated RNA.
7. The combination kit of claim 1 , wherein the at least one RNA is a stabilized RNA.
8. The combination kit of claim 1 , wherein the at least one RNA is at least partially G/C modified, wherein the G/C content of the at least one open reading frame of the at least one RNA of the composition is increased compared to the wild type open reading frame.
9. The combination kit of claim 1 , wherein the at least one RNA comprises a codon-optimized region, wherein the at least one open reading frame of the at least one RNA is codon-optimized.
10. The combination kit of claim 1 , wherein the at least one RNA of the composition is an mRNA.
11. The combination kit of claim 1 , wherein the at least one RNA is complexed with a carrier.
12. The combination kit of claim 11 , wherein the at least one RNA is complexed with a cationic carrier.
13. The combination kit of claim 12 , wherein the cationic carrier is a lipid.